CTRI/2022/09/045191
Not yet recruiting
未知
Evaluation of intraocular pressure lowering effect of 0.4% Ripasudil eye drops in patients with primary open angle glaucoma and ocular hypertension
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: H401- Open-angle glaucoma
- Sponsor
- Sankara eye hospital
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with Central Corneal Thickness corrected intraocular pressure more than or equal to 22mmHg which includes primary open angle glaucoma and ocular hypertension
Exclusion Criteria
- •Patients with history of ocular trauma
- •Patients with history of intraocular surgery
- •Secondary glaucomas like angle closure glaucoma, neovascular glaucoma, pseudo\-exfoliative glaucoma, pigmentary glaucoma
- •Patients with pre\-existing corneal diseases
- •Pre\-existing dry eye
- •Patients with allergic conjunctivitis
- •Pregnant and lactating women
- •Patients who are not willing for follow up
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A study of the intraocular pressure lowering effect of topical application of ripasudil in clinical practiceGlaucomaJPRN-UMIN000025466Kobe University Graduate School of Medicine130
Completed
Not Applicable
Evaluation of the Intraocular pressure lowering effect of Tafluprost and Latanoprost on normal tension GlaucomaGlaucomaJPRN-UMIN000002017Department of ophthalmology, Kyoto Prefectural University of Medicine30
Completed
Not Applicable
Comparison of intraocular pressure lowering effects among four prostaglandin analogues: parallel administration to the bilateral eyes of normal subjects.glaucoma, ocular hypertensionJPRN-UMIN000003810Department of Ophthalmology, Houju Memorial Hospital25
Not yet recruiting
Not Applicable
Generic Latanoprost: An Equivalent Comparison Open-labelled StudyTCTR20180115001Bausch & Lomb Co., Ltd.70
Completed
Phase 3
A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI StudyPrimary Open Angle Glaucoma or Ocular HypertensionNCT02822742Santen Pharmaceutical Co., Ltd.26